scholarly journals SC75741, A Novel c-Abl Inhibitor, Promotes the Clearance of TDP25 Aggregates via ATG5-Dependent Autophagy Pathway

2021 ◽  
Vol 12 ◽  
Author(s):  
Dongheng Zhou ◽  
Huanhuan Yan ◽  
Shuying Yang ◽  
Yuhong Zhang ◽  
Xiaoyan Xu ◽  
...  
Keyword(s):  
Nuclear Translocation ◽  
Regulatory Pathway ◽  
Neuroprotective Effects ◽  
Mutant Proteins ◽  
Abnormal Accumulation ◽  
Autophagy Pathway ◽  
Targeted Inhibition ◽  
Induced Aggregation ◽  
Lateral Sclerosis ◽  
Screening Approaches

Abnormal accumulation of TDP43-related mutant proteins in the cytoplasm causes amyotrophic lateral sclerosis (ALS). Herein, unbiased drug screening approaches showed that SC75741, a multi-target inhibitor, inhibited inflammation-induced aggregation by inhibiting NF-κB and also degraded already aggregated proteins by inhibiting c-Abl mediated autophagy-lysosomal pathway. We delineate the mechanism that SC75741 could markedly enhance TFEB nuclear translocation by an mTORC1-independent TFEB regulatory pathway. In addition, SC75741 enhanced the interaction between p62 with TDP25 and LC3C, thus promoting TDP25 degradation. Taken together, these findings show that SC75741 has beneficial neuroprotective effects in ALS. Our study elucidates that dual-targeted inhibition of c-Abl and NF-κB may be a potential treatment for TDP43 proteinopathies and ALS.

scholarly journals Clobetasol promotes neuromuscular plasticity in mice after motoneuronal loss via sonic hedgehog signaling, immunomodulation and metabolic rebalancing

2021 ◽  
Vol 12 (7) ◽  
Author(s):  
Nunzio Vicario ◽  
Federica M. Spitale ◽  
Daniele Tibullo ◽  
Cesarina Giallongo ◽  
Angela M. Amorini ◽  
...  
Keyword(s):  
Sonic Hedgehog ◽  
Hedgehog Signaling ◽  
Neural Regeneration ◽  
Metabolic Effects ◽  
Motor Impairments ◽  
Sonic Hedgehog Signaling ◽  
Neuroprotective Effects ◽  
Promising Target ◽  
Translational Approach ◽  
Lateral Sclerosis

AbstractMotoneuronal loss is the main feature of amyotrophic lateral sclerosis, although pathogenesis is extremely complex involving both neural and muscle cells. In order to translationally engage the sonic hedgehog pathway, which is a promising target for neural regeneration, recent studies have reported on the neuroprotective effects of clobetasol, an FDA-approved glucocorticoid, able to activate this pathway via smoothened. Herein we sought to examine functional, cellular, and metabolic effects of clobetasol in a neurotoxic mouse model of spinal motoneuronal loss. We found that clobetasol reduces muscle denervation and motor impairments in part by restoring sonic hedgehog signaling and supporting spinal plasticity. These effects were coupled with reduced pro-inflammatory microglia and reactive astrogliosis, reduced muscle atrophy, and support of mitochondrial integrity and metabolism. Our results suggest that clobetasol stimulates a series of compensatory processes and therefore represents a translational approach for intractable denervating and neurodegenerative disorders.

scholarly journals Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial)

BMJ Open ◽  
2017 ◽  
Vol 7 (8) ◽  
pp. e015434 ◽  
Author(s):  
Eleonora Dalla Bella ◽  
Irene Tramacere ◽  
Giovanni Antonini ◽  
Giuseppe Borghero ◽  
Margherita Capasso ◽  
...  
Keyword(s):  
Endoplasmic Reticulum ◽  
Amyotrophic Lateral Sclerosis ◽  
Placebo Group ◽  
Phase Ii ◽  
Critical Role ◽  
Protein Translation ◽  
Phase Iii ◽  
Protein Accumulation ◽  
Neuroprotective Effects ◽  
Lateral Sclerosis

IntroductionRecent studies suggest that endoplasmic reticulum stress may play a critical role in the pathogenesis of amyotrophic lateral sclerosis (ALS) through an altered regulation of the proteostasis, the cellular pathway-balancing protein synthesis and degradation. A key mechanism is thought to be the dephosphorylation of eIF2α, a factor involved in the initiation of protein translation. Guanabenz is an alpha-2-adrenergic receptor agonist safely used in past to treat mild hypertension and is now an orphan drug. A pharmacological action recently discovered is its ability to modulate the synthesis of proteins by the activation of translational factors preventing misfolded protein accumulation and endoplasmic reticulum overload. Guanabenz proved to rescue motoneurons from misfolding protein stress both in in vitro and in vivo ALS models, making it a potential disease-modifying drug in patients. It is conceivable investigating whether its neuroprotective effects based on the inhibition of eIF2α dephosphorylation can change the progression of ALS.Methods and analysesProtocolised Management In Sepsis is a multicentre, randomised, double-blind, placebo-controlled phase II clinical trial with futility design. We will investigate clinical outcomes, safety, tolerability and biomarkers of neurodegeneration in patients with ALS treated with guanabenz or riluzole alone for 6 months. The primary aim is to test if guanabenz can reduce the proportion of patients progressed to a higher stage of disease at 6 months compared with their baseline stage as measured by the ALS Milano-Torino Staging (ALS-MITOS) system and to the placebo group. Secondary aims are safety, tolerability and change in at least one biomarker of neurodegeneration in the guanabenz arm compared with the placebo group. Findings will provide reliable data on the likelihood that guanabenz can slow the course of ALS in a phase III trial.Ethics and disseminationThe study protocol was approved by the Ethics Committee of IRCCS ‘Carlo Besta Foundation’ of Milan (Eudract no. 2014-005367-32 Pre-results) based on the Helsinki declaration.

Abstract WMP45: Targeted Inhibition of the Alternative Complement Pathway Enhances Rehabilitation-Induced Cognitive and Motor Recovery in a Murine Model of Chronic Stroke

Stroke ◽  
2017 ◽  
Vol 48 (suppl_1) ◽  
Author(s):  
Ali Alawieh ◽  
Meredith Andersen ◽  
DeAnna L Adkins ◽  
Stephen Tomlinson
Keyword(s):  
Cognitive Performance ◽  
Infarct Volume ◽  
Alternative Pathway ◽  
Artery Occlusion ◽  
Motor Recovery ◽  
Acute Injury ◽  
Neuroprotective Effects ◽  
Recovery Processes ◽  
Targeted Inhibition ◽  
A Site

Introduction: Activation of inflammatory cascades after stroke exacerbate acute injury and limit response to rehabilitation (rehab). The complement (C) system is a prominent component of inflammatory injury after stroke, but can also contribute to neuroprotective recovery processes. We investigated the neuroprotective effects of CR2fH, a site-targeted C inhibitor that specifically inhibits the alternative pathway and prevents amplification of the C cascade. We assessed how CR2fH affects chronic outcomes, and how acute C inhibition impacts the response to rehab therapy. Methods: Mice were subjected to 1hr middle cerebral artery occlusion and 15 days of reperfusion. Mice were treated with CR2fH or vehicle and then randomized to normal housing or an enriched environment (EE) to model cognitive and motor rehab. Animals were assessed for infarct volume using MRI at days 4 and 14 after injury, and for their performance on several motor and cognitive tasks. Expression of inflammatory markers in the brain was assessed using high throughput Nanostring analysis and immunostaining. Results: Compared to vehicle or EE only, treatment with CR2fH 90 mins after cerebral ischemia significantly reduced infarct volume and improved motor and cognitive performance up to 15 days, as assessed with mNSS scores, corner task, locomotor activity, pasta handling, and passive avoidance tasks (p’s<0.01). Less prominent, although still significant improvement was also achieved when CR2fH was administered 6 or 12 hrs. after ischemia (p’s<0.05). EE alone did not significantly reduce infarct volume or improve performance on motor tasks, but resulted in a significant improvement in cognitive performance compared to vehicle (p’s<0.05). A combination of EE and CR2fH therapy resulted in a significant potentiation of cognitive and motor recovery compared to either single intervention (p’s<0.05). CR2fH related behavioral improvements correlated with reduction in C deposition and inflammatory microglial activation during recovery. Conclusions: Since a humanized version of CR2fH, TT30, was shown to be safe, tolerated and nonimmunogenic in humans, targeted inhibition of alternative C pathway is a candidate therapy to promote recovery and potentiate response to rehab after stroke.

scholarly journals Amphiphilic Nanocarrier Systems for Curcumin Delivery in Neurodegenerative Disorders

Medicines ◽  
2018 ◽  
Vol 5 (4) ◽  
pp. 126 ◽  
Author(s):  
Miora Rakotoarisoa ◽  
Angelina Angelova
Keyword(s):  
Neurodegenerative Disorders ◽  
Liquid Crystalline ◽  
Water Solubility ◽  
Neuronal Loss ◽  
Drug Solubility ◽  
Neuroprotective Effects ◽  
Slowing Down ◽  
Combination Treatments ◽  
Physico Chemical ◽  
Lateral Sclerosis

Neurodegenerative diseases have become a major challenge for public health because of their incurable status. Soft nanotechnology provides potential for slowing down the progression of neurodegenerative disorders by using innovative formulations of neuroprotective antioxidants like curcumin, resveratrol, vitamin E, rosmarinic acid, 7,8-dihydroxyflavone, coenzyme Q10, and fish oil. Curcumin is a natural, liposoluble compound, which is of considerable interest for nanomedicine development in combination therapies. The neuroprotective effects of combination treatments can involve restorative mechanisms against oxidative stress, mitochondrial dysfunction, inflammation, and protein aggregation. Despite the anti-amyloid and anti-tau potential of curcumin and its neurogenesis-stimulating properties, the utilization of this antioxidant as a drug in neuroregenerative therapies has huge limitations due to its poor water solubility, physico-chemical instability, and low oral bioavailability. We highlight the developments of soft lipid- and polymer-based delivery carriers of curcumin, which help improve the drug solubility and stability. We specifically focus on amphiphilic liquid crystalline nanocarriers (cubosome, hexosome, spongosome, and liposome particles) for the encapsulation of curcumin with the purpose of halting the progressive neuronal loss in Alzheimer’s, Parkinson’s, and Huntington’s diseases and amyotrophic lateral sclerosis (ALS).

scholarly journals Cerebral sterile inflammation in neurodegenerative diseases

2020 ◽  
Vol 40 (1) ◽  
Author(s):  
Kento Otani ◽  
Takashi Shichita
Keyword(s):  
Immune Responses ◽  
Neurodegenerative Diseases ◽  
Molecular Mechanisms ◽  
Therapeutic Agents ◽  
Sterile Inflammation ◽  
Cellular Damage ◽  
Cellular Mechanisms ◽  
Abnormal Accumulation ◽  
The Brain ◽  
Lateral Sclerosis

AbstractTherapeutic strategies for regulating neuroinflammation are expected in the development of novel therapeutic agents to prevent the progression of central nervous system (CNS) pathologies. An understanding of the detailed molecular and cellular mechanisms of neuroinflammation in each CNS disease is necessary for the development of therapeutics. Since the brain is a sterile organ, neuroinflammation in Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS) is triggered by cerebral cellular damage or the abnormal accumulation of inflammatogenic molecules in CNS tissue through the activation of innate and acquired immunity. Inflammation and CNS pathologies worsen each other through various cellular and molecular mechanisms, such as oxidative stress or the accumulation of inflammatogenic molecules induced in the damaged CNS tissue. In this review, we summarize the recent evidence regarding sterile immune responses in neurodegenerative diseases.

scholarly journals Targeting connexin 43 provides anti-inflammatory effects after intracerebral hemorrhage injury by regulating YAP signaling

2020 ◽  
Vol 17 (1) ◽  
Author(s):  
Hailong Yu ◽  
Xiang Cao ◽  
Wei Li ◽  
Pinyi Liu ◽  
Yuanyuan Zhao ◽  
...  
Keyword(s):  
Intracerebral Hemorrhage ◽  
Connexin 43 ◽  
Nuclear Translocation ◽  
Neurological Deficits ◽  
Proximity Ligation Assay ◽  
Neuroprotective Effects ◽  
Cx43 Expression ◽  
Anti Inflammatory

Abstract Background In the central nervous system (CNS), connexin 43 (Cx43) is mainly expressed in astrocytes and regulates astrocytic network homeostasis. Similar to Cx43 overexpression, abnormal excessive opening of Cx43 hemichannels (Cx43Hcs) on reactive astrocytes aggravates the inflammatory response and cell death in CNS pathologies. However, the role of excessive Cx43Hc opening in intracerebral hemorrhage (ICH) injury is not clear. Methods Hemin stimulation in primary cells and collagenase IV injection in C57BL/6J (B6) mice were used as ICH models in vitro and in vivo. After ICH injury, the Cx43 mimetic peptide Gap19 was used for treatment. Ethidium bromide (EtBr) uptake assays were used to measure the opening of Cx43Hcs. Western blotting and immunofluorescence were used to measure protein expression. qRT-PCR and ELISA were used to determine the levels of cytokines. Coimmunoprecipitation (Co-IP) and the Duolink in situ proximity ligation assay (PLA) were applied to measure the association between proteins. Results In this study, Cx43 expression upregulation and excessive Cx43Hc opening was observed in mice after ICH injury. Delayed treatment with Gap19 significantly alleviated hematoma volume and neurological deficits after ICH injury. In addition, Gap19 decreased inflammatory cytokine levels in the tissue surrounding the hematoma and decreased reactive astrogliosis after ICH injury in vitro and in vivo. Intriguingly, Cx43 transcriptional activity and expression in astrocytes were significantly increased after hemin stimulation in culture. However, Gap19 treatment downregulated astrocytic Cx43 expression through the ubiquitin-proteasome pathway without affecting Cx43 transcription. Additionally, our data showed that Gap19 increased Yes-associated protein (YAP) nuclear translocation. This subsequently upregulated SOCS1 and SOCS3 expression and then inhibited the TLR4-NFκB and JAK2-STAT3 pathways in hemin-stimulated astrocytes. Finally, the YAP inhibitor, verteporfin (VP), reversed the anti-inflammatory effect of Gap19 in vitro and almost completely blocked its protective effects in vivo after ICH injury. Conclusions This study provides new insight into potential treatment strategies for ICH injury involving astroglial Cx43 and Cx43Hcs. Suppression of abnormal astroglial Cx43 expression and Cx43Hc opening by Gap19 has anti-inflammatory and neuroprotective effects after ICH injury.

scholarly journals Identification of the human c-myc protein nuclear translocation signal.

1988 ◽  
Vol 8 (10) ◽  
pp. 4048-4054 ◽  
Author(s):  
C V Dang ◽  
W M Lee
Keyword(s):  
Nuclear Localization ◽  
Nuclear Translocation ◽  
Vero Cells ◽  
Embryo Cell ◽  
Nuclear Accumulation ◽  
Nuclear Targeting ◽  
Mutant Proteins ◽  
Chicken Muscle ◽  
Localization Signal ◽  
Muscle Pyruvate Kinase

We identified and characterized two regions of the human c-myc protein that target proteins into the nucleus. Using mutant c-myc proteins and proteins that fuse portions of c-myc to chicken muscle pyruvate kinase, we found that residues 320 to 328 (PAAKRVKLD; peptide M1) induced complete nuclear localization, and their removal from c-myc resulted in mutant proteins that distributed in both the nucleus and cytoplasm but retained rat embryo cell cotransforming activity. Residues 364 to 374 (RQRRNELKRSP; peptide M2) induced only partial nuclear targeting, and their removal from c-myc resulted in mutant proteins that remained nuclear but were cotransformationally inactive. We conjugated synthetic peptides containing M1 or M2 to human serum albumin and microinjected the conjugate into the cytoplasm of Vero cells. The peptide containing M1 caused rapid and complete nuclear accumulation, whereas that containing M2 caused slower and only partial nuclear localization. Thus, M1 functions as the nuclear localization signal of c-myc, and M2 serves some other and essential function.

The Role of the Transcription Factor NFAT in the Pathogenesis of Non-Hodgkin’s Lymphomas.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 2371-2371
Author(s):  
Martin R. Mueller ◽  
Yoshiteru Sasaki ◽  
Sonia Sharma ◽  
Klaus Rajewsky ◽  
Anjana Rao
Keyword(s):  
Nuclear Export ◽  
Nuclear Translocation ◽  
Consensus Sequence ◽  
Resting Cells ◽  
Docking Site ◽  
Mutant Proteins ◽  
Nfat Activation ◽  
Hodgkin's Lymphomas ◽  
The Impact

Abstract NFAT is a family of highly phosphorylated proteins residing in the cytoplasm of resting cells. Upon dephosphorylation by the Ca2+/calmodulin-dependent serine phosphatase calcineurin, NFAT translocates to the nucleus, where it induces the transcription of a large number of genes necessary for a productive immune response. NFAT signalling has also been implicated in lymphocyte homeostasis and its deregulation has been suggested to be involved in the pathogenesis of different malignancies. A recent immunohistochemical evaluation of approximately 300 Non-Hodgkin’s Lymphoma biopsy samples showed overexpression of NFAT2 in the majority of specimens with strong nuclear translocation in certain histologic subtypes (DLBCL, Burkitt’s Lymphoma) presumably reflecting activation of the NFAT pathway as part of their pathogenesis. Other recent studies have shown that NFAT activation leads to increased expression of different cell survival factors (CD154, BLyS) in several lymphoma subtypes (DLBCL, MCL). To study the role of constitutive activation of the NFAT pathway on lymphomagenesis, we generated several hyperactivable NFAT mutants which will be used to generate transgenic mice expressing the mutant proteins from the ROSA26 locus. Here, we present the in vitro characterization of these hyperactivable NFAT proteins in cell lines and primary lymphocytes. The major docking site for calcineurin is located at the N terminus of the NFAT regulatory domain and has the consensus sequence PxIxIT (e.g. SPRIEIT in NFAT1 and NFAT2). Substitution of the SPRIEIT sequence of NFAT with HPVIVIT, a higher-affinity version obtained by peptide selection, increases the basal calcineurin sensitivity of the protein significantly. Similarly, a major kinase for NFAT is CK1, and mutation of the CK1 docking site (FSILF to ASILA in NFAT1, FDFEF to ADAEA in NFAT2) also leads to partial nuclear localization of NFAT proteins by decreasing rephosphorylation and nuclear export. In the current analysis we compared the different hyperactivable NFAT proteins with respect to dephosphorylation status and nuclear translocation using western blotting and immunocytochemistry. Whereas the wildtype NFAT protein was entirely localized in the cytoplasm and completely phosphorylated under resting conditions, we observed an increasing degree of nuclear translocation and dephosphorylation for the different mutant proteins (ASILA 20%, VIVIT 30–40%, ASILA-VIVIT 50–70%). This system will allow us to study the impact of different levels of NFAT activation on the pathogenesis of lymphomas in vivo.

Sign in / Sign up

Export Citation Format

Share Document